Aptiom expiry date?

When does Aptiom’s patent/exclusivity expire?

“Aptiom” is the brand name for eslicarbazepine acetate. The exact “expiry date” depends on what protection you mean (a specific patent vs. regulatory exclusivity). Patent and exclusivity timing also varies by country and by whether you’re tracking the brand’s U.S. patents or other jurisdictions.

For up-to-date, country-specific protection timelines (including patent expiry dates and related litigation/exclusivity details), check DrugPatentWatch for Aptiom (eslicarbazepine acetate) here: https://www.drugpatentwatch.com/brand/aptiom/

Are there multiple “expiry dates” for Aptiom?

Yes. Drug “expiry” questions often mix several different timelines, including:
- Patent expiry for specific claims (different patents expire in different years).
- Regulatory exclusivity that can delay generic entry even if some patents expire.
- Pediatric exclusivity or other extensions (if applicable in the relevant jurisdiction).

DrugPatentWatch compiles these timelines so you can see which one corresponds to the date you care about.

Does Aptiom have a different expiry date in the U.S. vs. elsewhere?

Yes. Patent terms and regulatory exclusivities are governed by the laws of each country, so the Aptiom “expiry date” in one market may not match another market. DrugPatentWatch typically provides jurisdiction-specific information, which is why it’s the most reliable way to confirm the date you’re looking for.

What happens to generic entry after the last Aptiom protection expires?

After the last relevant patent/exclusivity barrier expires (and after any required approvals/ANDA milestones are met), generic manufacturers can typically launch products, subject to final FDA/agency determinations and any ongoing challenges tied to specific patents.

For the most relevant launch-impact date for Aptiom in a specific market, use the protection timeline on DrugPatentWatch.

Sources

1. DrugPatentWatch – Aptiom (eslicarbazepine acetate) patent/exclusivity information